CA2878267A1 - Methods of treating pediatric metabolic syndrome - Google Patents
Methods of treating pediatric metabolic syndrome Download PDFInfo
- Publication number
- CA2878267A1 CA2878267A1 CA2878267A CA2878267A CA2878267A1 CA 2878267 A1 CA2878267 A1 CA 2878267A1 CA 2878267 A CA2878267 A CA 2878267A CA 2878267 A CA2878267 A CA 2878267A CA 2878267 A1 CA2878267 A1 CA 2878267A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- baseline
- compared
- hdl
- per day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261666437P | 2012-06-29 | 2012-06-29 | |
| US61/666,437 | 2012-06-29 | ||
| PCT/US2013/048241 WO2014004861A2 (en) | 2012-06-29 | 2013-06-27 | Methods of treating pediatric metabolic syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2878267A1 true CA2878267A1 (en) | 2014-01-03 |
Family
ID=49778759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2878267A Abandoned CA2878267A1 (en) | 2012-06-29 | 2013-06-27 | Methods of treating pediatric metabolic syndrome |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20140005264A1 (zh) |
| EP (2) | EP2866800A4 (zh) |
| JP (3) | JP2015523360A (zh) |
| CN (2) | CN104837487A (zh) |
| AU (1) | AU2013284464A1 (zh) |
| BR (1) | BR112014032699A2 (zh) |
| CA (1) | CA2878267A1 (zh) |
| HK (1) | HK1204272A1 (zh) |
| RU (2) | RU2015102808A (zh) |
| WO (1) | WO2014004861A2 (zh) |
| ZA (1) | ZA201500026B (zh) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2334295T3 (en) | 2008-09-02 | 2017-10-09 | Amarin Pharmaceuticals Ie Ltd | PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME |
| WO2010127103A1 (en) | 2009-04-29 | 2010-11-04 | Amarin Pharma, Inc. | Stable pharmaceutical composition and methods of using same |
| AU2010241567B2 (en) | 2009-04-29 | 2013-10-31 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
| US8455472B2 (en) | 2009-06-15 | 2013-06-04 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| KR101798670B1 (ko) | 2009-09-23 | 2017-11-16 | 아마린 코포레이션 피엘씨 | 오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법 |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| NZ727980A (en) | 2010-11-29 | 2018-08-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
| RS61557B1 (sr) | 2012-06-29 | 2021-04-29 | Amarin Pharmaceuticals Ie Ltd | Postupci za smanjenje rizika od kardiovaskularnog događaja kod pacijenta na terapiji statinom primenom etil estra eikozapentaenske kiseline |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| WO2020068163A1 (en) | 2018-09-24 | 2020-04-02 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
| WO2020064690A1 (en) * | 2018-09-27 | 2020-04-02 | Société des Produits Nestlé S.A. | Markers of risk to develop insulin resistance during childhood and young adulthood |
| JPWO2022149342A1 (zh) * | 2021-01-06 | 2022-07-14 | ||
| KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| WO2006017627A2 (en) * | 2004-08-06 | 2006-02-16 | Barry Sears | Dietary compositions comprising docosahexaenoic acid and eicosapentaenoic acid and use thereof for treating insulin resistance |
| CA2628305C (en) * | 2005-11-11 | 2014-05-06 | Mochida Pharmaceutical Co., Ltd. | Jelly composition |
| US20100062057A1 (en) * | 2008-09-10 | 2010-03-11 | Pronova BioPharma Norge AS. | Formulation |
| RU2728825C2 (ru) * | 2010-03-04 | 2020-07-31 | Амарин Фармасьютикалз Айрлэнд Лимитед (Апил) | Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания |
| CN102391112B (zh) * | 2011-10-31 | 2014-06-04 | 赵永俊 | 一种工业化生产二十碳五烯酸乙酯的方法 |
-
2013
- 2013-06-27 RU RU2015102808A patent/RU2015102808A/ru not_active Application Discontinuation
- 2013-06-27 AU AU2013284464A patent/AU2013284464A1/en not_active Abandoned
- 2013-06-27 US US13/928,863 patent/US20140005264A1/en not_active Abandoned
- 2013-06-27 RU RU2020125675A patent/RU2020125675A/ru unknown
- 2013-06-27 JP JP2015520515A patent/JP2015523360A/ja active Pending
- 2013-06-27 EP EP13808719.2A patent/EP2866800A4/en not_active Withdrawn
- 2013-06-27 WO PCT/US2013/048241 patent/WO2014004861A2/en active Application Filing
- 2013-06-27 BR BR112014032699A patent/BR112014032699A2/pt not_active Application Discontinuation
- 2013-06-27 CN CN201380040236.1A patent/CN104837487A/zh active Pending
- 2013-06-27 EP EP19217737.6A patent/EP3682875A3/en not_active Withdrawn
- 2013-06-27 CN CN201910503526.4A patent/CN110101692A/zh active Pending
- 2013-06-27 CA CA2878267A patent/CA2878267A1/en not_active Abandoned
-
2015
- 2015-01-05 ZA ZA2015/00026A patent/ZA201500026B/en unknown
- 2015-05-20 HK HK15104817.6A patent/HK1204272A1/zh unknown
-
2017
- 2017-08-09 US US15/672,603 patent/US20180085334A1/en not_active Abandoned
- 2017-10-24 JP JP2017204925A patent/JP2018065807A/ja active Pending
-
2018
- 2018-08-02 US US16/052,724 patent/US20190183839A1/en not_active Abandoned
-
2019
- 2019-07-17 JP JP2019132302A patent/JP2019206552A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2015102808A (ru) | 2016-08-20 |
| EP3682875A2 (en) | 2020-07-22 |
| WO2014004861A2 (en) | 2014-01-03 |
| BR112014032699A2 (pt) | 2017-06-27 |
| ZA201500026B (en) | 2016-03-30 |
| CN104837487A (zh) | 2015-08-12 |
| EP3682875A3 (en) | 2020-10-21 |
| CN110101692A (zh) | 2019-08-09 |
| US20180085334A1 (en) | 2018-03-29 |
| US20140005264A1 (en) | 2014-01-02 |
| JP2015523360A (ja) | 2015-08-13 |
| AU2013284464A1 (en) | 2015-01-22 |
| EP2866800A4 (en) | 2015-12-16 |
| JP2018065807A (ja) | 2018-04-26 |
| WO2014004861A3 (en) | 2014-02-27 |
| JP2019206552A (ja) | 2019-12-05 |
| HK1204272A1 (zh) | 2015-11-13 |
| RU2020125675A (ru) | 2020-09-16 |
| US20190183839A1 (en) | 2019-06-20 |
| EP2866800A2 (en) | 2015-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190183839A1 (en) | Methods of treating pediatric metabolic syndrome | |
| JP6419927B2 (ja) | 対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法 | |
| US10966968B2 (en) | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof | |
| RU2686315C2 (ru) | Способы лечения гипертриглицеридемии | |
| US20150250757A1 (en) | Methods for treating hypertriglyceridemia | |
| US20200108041A1 (en) | Methods of reducing ldl-p | |
| US20140221676A1 (en) | Compositions and methods for treating and/or preventing cardiovascular disease | |
| US20140004183A1 (en) | Methods for treating cardiovascular disease in statin-tolerant subjects | |
| WO2014134466A1 (en) | Co-administration of atorvastatin and ethyl eicosapentaenoic acid or a derivative thereof | |
| KR20120016677A (ko) | 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법 | |
| EP2775837A1 (en) | Methods of treating hypertriglyceridemia | |
| RU2797547C2 (ru) | Способы лечения гипертриглицеридемии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180614 |
|
| FZDE | Discontinued |
Effective date: 20220603 |
|
| FZDE | Discontinued |
Effective date: 20220603 |